Insmed mailed a $750 million follow-on public equity offering following positive clinical data in hypertension. The financing round highlights growing investor confidence fueled by clinical progress. Other biopharma companies including Enliven, Cabaletta, and Keymed also disclosed recent financings. Caris Life Sciences plans an IPO, while Odyssey withdrew its listing plans. The report underscores sustained capital market activity supporting late-stage development across biopharma.